ClinicalTrials.gg
RecruitingNCT04995341BabySTEPS2Updated May 22, 2026

Retinal Microanatomy in Retinopathy of Prematurity (BabySTEPS2)

An interventional study of Investigational ultracompact OCT and OCTA system and retinal photographs in Retinopathy of Prematurity, sponsored by Duke University. Recruiting at 2 sites in United States. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Duke University · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Aug 2021; still recruiting 5 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
236
Allocation
Non-randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Retinopathy of Prematurity with a site in United States — 6 open to participants now, 10 under way, none of them phase 3. Retinopathy of Prematurity · United States.

Planned enrollment
8th of 32
236 · median 114
Started
2021
with 2 others
No phase
10 of 51
2 open now
Registered
43rd of 51
by date
Lead sponsor
4 of 51
Duke University

Among the 51 studies in Retinopathy of Prematurity with a site in United States, this one is the 8th largest by planned enrollment of the 32 interventional ones that give a count, is one of 3 that started in 2021, is one of 10 with no phase, and was the 43rd registered.

Retinopathy of Prematurity

170 studies on the registry are indexed under Retinopathy of Prematurity; 28 are open to participants now.

Browse Retinopathy of Prematurity studies →

Open to participants now

6 of the 51 studies in Retinopathy of Prematurity with a site in United States are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 19 Retinopathy of Prematurity studies recruiting now, 7 (37%) set no upper age limit and 12 (63%) stop at 75 or younger; 19 take children under 18; 4 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Retinopathy of Prematurity with a site in United States, or all of them as a file.
02

Study summary

Retinopathy of prematurity (ROP) is a disorder of development of the neural retina and its vasculature that can impact vision in vulnerable preterm neonates for a lifetime. This study tests high-speed optical coherence tomography (OCT) technology compared to conventional color photographs at the bedside of very preterm infants in the intensive care nursery, to characterize previously unseen abnormalities that can predict a need for referral for ROP treatment, or poor visual or neurological development later in life, up to pre-school age. Our long-term goal is to help improve preterm infant health and vision via objective bedside imaging and analysis that characterizes early critical indicators of ROP, and poor visual function and neurological development, which will rapidly translate to better early intervention and improved future care.

Read the detailed description

As an increasing percentage of preterm infants survive worldwide, the number of infants at risk for retinopathy of prematurity (ROP) is increasing. These infants are also at high risk for future abnormal visual function and neurodevelopment. While current screening approaches address identifying eyes for treatment of severe ROP, there are no attempts to address the later subnormal vision of many preterm infants. In part, this is due to a lack of information about the retina beyond that of retinal vascular development. In addition, the most common method to screen for ROP remains indirect ophthalmoscopic examination by physicians with annotated drawings for documentation, a method proven to be poorly reproducible and stressful to the fragile infant. Bedside retinal photographs enable documentation and the possibility for telemedicine approaches, but lack information about retinal microanatomy, are poor quality in darkly pigmented eyes and also are stressful to the infant because of the required light exposure. We need an infant-friendly, more practical approach to evaluate ROP efficiently and additional information about ocular and neurovascular development that could lead to improved clinical care.

This research builds on our group's ability to reliably capture and process non-contact, infrared optical coherence tomography (OCT) and OCT-angiography of retinal microanatomy and microvasculature at high speed, across a wide field of view, and at the bedside in preterm infants. Our overall objectives are threefold: first, to evaluate infant microanatomy and microvascular flow findings relevant to vision and neurodevelopmental outcomes in children; second, to translate and test our imaging achievements for real-world use by nurses at the bedside and for better clinical insight and feedback; and third, to gather additional data in eyes that progress to treatment and dive deeper into the insight that they provide into pathways of disease in ROP. The investigational OCT imaging will be used in this research to gather information that is otherwise not accessible to the physician. This research will lay the groundwork for future use of infant OCT markers to guide care.

03

Conditions studied

  • Retinopathy of Prematurity

Keywords

  • Optical Coherence Tomography (OCT)
  • Optical Coherence Tomography Angiography (OCTA)
  • Retinopathy of Prematurity
  • Neurodevelopment
  • Visual Acuity
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children previously enrolled in BabySTEPS1 (Pro00069721) that have already consented to being contacted for this school age follow on study, Cohort 1 only
  • Parent/Legal Guardian is able and willing to consent to study participation with follow up approximately between 4.5 and 5 years of age (consent available in Spanish* and English) (SA 1 only)
  • Parent/Legal Guardian is able and willing to consent to study participation for the infant (SA 2 and 2c only)
  • Infant/child undergoing clinically-indicated examination under anesthesia that may or may not have eye pathology (SA 2 only)
  • Infant inborn or outborn at (SA 2 only):
  • Duke Hospital (Years 1, 2 and 3) with birth weight ≤1000 grams, and/or 20 0/7 to 28/ 6/7 (\<29 weeks) gestational age
  • Duke Hospital (Years 1, 2 and 3) at high risk to require treatment for ROP irrespective of birth weight and gestational age (e.g. pre-plus, severe ROP in zone 1, APROP, etc.)
  • Duke Regional Hospital (Years 4 and 5) that meets the American Association of Pediatrics eligibility of ROP screening (Infants with a birth weight of ≤1500 g or gestational age of 30 weeks)
  • Adults (over the age of 18 years) that may or may not have eye pathology (SA 2 only)

Exclusion criteria

Exclusion Criteria:

  • Participant or Parent/Legal Guardian unwilling or unable to provide consent
  • Adult participant or infant/child has a health or eye condition that preclude eye examination or retinal imaging (e.g. corneal opacity such as with Peter's anomaly or cataract) (SA2 only)
  • Infant has a health condition, other than prematurity, that has a profound impact on brain development (e.g. anencephaly) (SA2 only)
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Single group
Masking
Double (Investigator, Outcomes assessor)
Enrollment
236 participants (estimated)

Study arms

  • Experimental
    Cohort 1: Functional and structural outcomes in children after bedside OCT imaging in infancy

    109 pediatric participants who were previously enrolled in BabySTEPS1 from July 22, 2016 - December 30, 2020 will be enrolled for follow-up neurodevelopmental testing, visual acuity, visual function testing and investigational retinal imaging

    Device: Investigational ultracompact OCT and OCTA system

  • Experimental
    Cohort 2: Test of bedside OCT imaging data to predict RW-ROP or ROP progression

    294 infants at risk for retinopathy of prematurity: 176 will be enrolled and have investigational bedside OCT retinal imaging, and their data will be combined with that from 118 infants who had similar imaging in BabySTEPS1 for analysis of the total group versus the indirect ophthalmoscopic clinical exam data.

    Device: Investigational ultracompact OCT and OCTA system

  • Experimental
    Cohort 3: Comparison of ROP imaging with investigational OCT versus retinal camera

    102 infants, who are a sub-group of the 132 enrolled in Cohort 2, will also have imaging with a conventional, commercially available, retinal camera system to compare utility, stress, and prediction and documentation of referral-warranted ROP between the camera images and those from investigational OCT.

    Device: Investigational ultracompact OCT and OCTA system · Device: retinal photographs

  • Experimental
    Cohort 4: Adult and pediatric participants enrolled for imaging during system development

    12 awake healthy adult controls and 6 pediatric participants undergoing examination under anesthesia in the operating room will be imaged with the investigational bedside OCT for the purpose of technological development.

    Device: Investigational ultracompact OCT and OCTA system

Interventions

  • DeviceInvestigational ultracompact OCT and OCTA system

    Handheld bedside retinal OCT and OCT angiography imaging with an investigational portable system with ultracompact handpiece

    Also known as: optical coherence tomography, optical coherence tomography angiography

  • Deviceretinal photographs

    retinal photographs with a commercial portable bedside widefield fundus camera system

    Also known as: RetCam

06

What researchers measure

Primary outcomes

  1. Optotype Visual acuity scores (Cohort 1 only)

    HOTV visual acuity at the 5-year study visit. Visual acuity is recorded as the last line of the HOTV chart on which over 50% of the 4 symbols are identified correctly identified by the participant. If the participant is not capable of performing HOTV, then Teller cards will be used for preferential-looking visual acuity assessment. With Teller, acuity is determined by the smallest cycles per degree.

    Time frame: 5-year study visit

  2. Visual function scores (Cohort 1 only)

    Visual function at the 4.75-year visit is measured by the presence or absence of strabismus, nystagmus, and amblyopia

    Time frame: 4.75-year study visit

  3. Neurodevelopmental scores at 2-year study visit (Cohort 1 only)

    Neurodevelopmental testing at the 2-year neurodevelopment study visit: a) Bayley Scales of Infant and Toddler Development: Scores motor skills with the standardized mean motor score of 100; less than 85 indicates mild impairment; less than 70 indicates moderate to severe impairment.

    Time frame: 2-year study visit

  4. Retinal thickness at the fovea and surrounding optic nerve as measured by OCT reading (Cohort 1-3)

    Retinal thickness (microns) at the fovea and surrounding optic nerve.

    Time frame: Up to 42 weeks post-menstrual age

  5. Microanatomy as measured by OCT reading

    Combination of presence and severity of: retinal vessel tortuosity, vascular abnormality score by OCT (VASO), aggressive ROP, extra retinal neovascularization, vitreous abnormalities, shunt vessels, retinoschisis and retinal detachment.

    Time frame: Up to 42 weeks post-menstrual age

  6. Microanatomy as measured by retinal photo reading (Cohort 3 only)

    Combination of presence and severity of retinal vessel tortuosity, aggressive ROP, extra retinal neovascularization, shunt vessels, vitreous opacities, vitreous haze, retinoschisis and retinal detachment.

    Time frame: Up 42 weeks post-menstrual age

  7. Microanatomy as measured by clinical exam (Cohort 1-3)

    Clinical determination of combination presence and severity of retinal vessel tortuosity, aggressive ROP, extra retinal neovascularization, shunt vessels, vitreous opacities, vitreous haze, retinoschisis and retinal detachment.

    Time frame: Up to 42 weeks post-menstrual age

  8. Measurement of stress of imaging (Cohort 3 only)

    Assessment of stress and discomfort using modified CRIES score (crying 0-4; facial expression 0-2; heart rate beats per minute; change in respiratory support) during each eye imaging and compared to baseline pre-imaging score adverse events recorded during imaging (bradycardia, tachycardia, desaturation, emesis, and ocular adverse events e.g. conjunctival hemorrhage)

    Time frame: Up to 42 weeks post-menstrual age

  9. Assessment of ease of imaging (Cohort 3 only)

    Based on Likert scales (1-5)

    Time frame: Up to 42 weeks post-menstrual age

  10. ROP vascular severity score (Cohort 3 only)

    Based on a combination of relative retinal vessel tortuosity score, extraretinal neovascularization and aggressive ROP.

    Time frame: Up to 42 weeks post-menstrual age

Secondary outcomes

  1. Neurodevelopmental scores at 5-year study visit (Cohort 1 only)

    Wechsler Preschool and Primary Scale of Intelligence - 4: Measures specific aspects of working memory. Each subtest produces scaled scores from 1 to 19, with average scores between 7 and 12.

    Time frame: 5-year study visit

  2. Neurodevelopmental scores at 5-year study visit (Cohort 1 only)

    Movement Assessment Battery for Children: Comprehensive measurement of motor skills \& is a well-known standardized test for detecting movement difficulty in children. Higher scores reflect more motor impairment.

    Time frame: 5-year study visit

  3. Neurodevelopmental scores at 5-year study visit (Cohort 1 only)

    Developmental Test of Visual Motor Integration: Non-verbal assessment that gauges the degree to which participants can integrate visual and motor abilities. Lower scores reflect more impairment.

    Time frame: 5-year study visit

  4. Neurodevelopmental parental questionnaires at 5-year study visit (Cohort 1 only)

    Child Behavior Checklist: 113 questions scored on a 3-point Likert frequency scale; scores below 93rd% are considered normal, scores 93-97th% are borderline and score above 97th% is in clinical range.

    Time frame: 5-year study visit

  5. Neurodevelopmental parental questionnaires at 5-year study visit (Cohort 1 only)

    Behavior Rating Inventory of Executive Functioning: 75 items in terms of frequency on a 3-point scale; raw scores for each scale are summed and T-scores (performance score where 50 is average and standard deviation is 10 points) are used.

    Time frame: 5-year study visit

  6. Neurodevelopmental parental questionnaires at 5-year study visit (Cohort 1 only)

    Social Communication Questionnaire: Total score is interpreted with a higher score in reference to cut-off (e.g. of 15) to suggest likelihood of autism spectrum.

    Time frame: 5-year study visit

Other outcomes

  1. Axial length as measured in millimeters (Cohort 1 only)

    Time frame: 4.75-year study visit

  2. OCT grading from commercial OCT device

    Based on combination of presence or absence of retinal vessel dragging, retinal detachment and fundus pigmentation (blond, medium, dark) from ultra-widefield fundus imaging; and OCT imaging (nerve fiber layer and center foveal thickness).

    Time frame: 4.75-year study visit

  3. Reference standard score for ROP vascular severity (Cohort 3 only)

    The reference standard is the consensus determination based on a combination of OCT and photographic imaging of the relative retinal vessel tortuosity score \& clinical ROP exam determination of plus, pre-plus, neither, and for all 3 assessments extraretinal neovascularization and aggressive ROP.

    Time frame: Up to 42 weeks post-menstrual age

07

Study locations

1 of 2 sites recruiting
  • Duke University Eye Center
    Durham, North Carolina 27705, United States
    Recruiting
    • Cynthia A Toth, MD · Contactcynthia.toth@duke.edu · 9196845631
    • Michelle N McCall, MCAPM, BA · Contactmichelle.mccall@duke.edu · 9196840544
    • Sharon F Freedman, MD · Sub investigator
    • Charles M Cotten, MD, MHS · Sub investigator
    • Joseph A Izatt, PhD · Sub investigator
    • Christian Viehland, PhD · Sub investigator
    • Kathryn E Gustafson, MD · Sub investigator
    • Lejla Vajzovic, MD · Sub investigator
    • Susapin G Prakalapakorn, MD · Sub investigator
    • Xi Chen, MD, PhD · Sub investigator
    • Sara Grace, MD · Sub investigator
  • University of Pennsylvania, Center for Preventive Ophthalmology and Biostatistics
    Philadelphia, Pennsylvania 19104, United States
    Not yet recruiting
08

References and documents

Publications

  • Mangalesh S, Chen X, Tran-Viet D, Viehland C, Freedman SF, Toth CA. ASSESSMENT OF THE RETINAL STRUCTURE IN CHILDREN WITH INCONTINENTIA PIGMENTI. Retina. 2017 Aug;37(8):1568-1574. doi: 10.1097/IAE.0000000000001395. PubMed 28085775 ↗
  • Lee J, El-Dairi MA, Tran-Viet D, Mangalesh S, Dandridge A, Jiramongkolchai K, Viehland C, Toth CA. LONGITUDINAL CHANGES IN THE OPTIC NERVE HEAD AND RETINA OVER TIME IN VERY YOUNG CHILDREN WITH FAMILIAL EXUDATIVE VITREORETINOPATHY. Retina. 2019 Jan;39(1):98-110. doi: 10.1097/IAE.0000000000001930. PubMed 29190238 ↗
  • Chen X, Mangalesh S, Tran-Viet D, Freedman SF, Vajzovic L, Toth CA. Fluorescein Angiographic Characteristics of Macular Edema During Infancy. JAMA Ophthalmol. 2018 May 1;136(5):538-542. doi: 10.1001/jamaophthalmol.2018.0467. PubMed 29621379 ↗
  • Hsu ST, Chen X, House RJ, Kelly MP, Toth CA, Vajzovic L. Visualizing Macular Microvasculature Anomalies in 2 Infants With Treated Retinopathy of Prematurity. JAMA Ophthalmol. 2018 Dec 1;136(12):1422-1424. doi: 10.1001/jamaophthalmol.2018.3926. No abstract available. PubMed 30326081 ↗
  • Chen X, Mangalesh S, Dandridge A, Tran-Viet D, Wallace DK, Freedman SF, Toth CA. Spectral-Domain OCT Findings of Retinal Vascular-Avascular Junction in Infants with Retinopathy of Prematurity. Ophthalmol Retina. 2018 Sep;2(9):963-971. doi: 10.1016/j.oret.2018.02.001. Epub 2018 Mar 21. PubMed 30506013 ↗
  • Hsu ST, Chen X, Ngo HT, House RJ, Kelly MP, Enyedi LB, Materin MA, El-Dairi MA, Freedman SF, Toth CA, Vajzovic L. Imaging Infant Retinal Vasculature with OCT Angiography. Ophthalmol Retina. 2019 Jan;3(1):95-96. doi: 10.1016/j.oret.2018.06.017. Epub 2018 Jul 26. No abstract available. PubMed 30935662 ↗
  • Mangalesh S, Bleicher ID, Chen X, Viehland C, LaRocca F, Izatt JA, Freedman SF, Hartnett ME, Toth CA. Three-dimensional pattern of extraretinal neovascular development in retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2019 Apr;257(4):677-688. doi: 10.1007/s00417-019-04274-6. Epub 2019 Feb 21. PubMed 30790072 ↗
  • Viehland C, Chen X, Tran-Viet D, Jackson-Atogi M, Ortiz P, Waterman G, Vajzovic L, Toth CA, Izatt JA. Ergonomic handheld OCT angiography probe optimized for pediatric and supine imaging. Biomed Opt Express. 2019 Apr 29;10(5):2623-2638. doi: 10.1364/BOE.10.002623. eCollection 2019 May 1. PubMed 31143506 ↗
  • Smith LEH, Hellstrom A, Stahl A, Fielder A, Chambers W, Moseley J, Toth C, Wallace D, Darlow BA, Aranda JV, Hallberg B, Davis JM; Retinopathy of Prematurity Workgroup of the International Neonatal Consortium. Development of a Retinopathy of Prematurity Activity Scale and Clinical Outcome Measures for Use in Clinical Trials. JAMA Ophthalmol. 2019 Mar 1;137(3):305-311. doi: 10.1001/jamaophthalmol.2018.5984. PubMed 30543348 ↗
  • Hsu ST, Ngo HT, Stinnett SS, Cheung NL, House RJ, Kelly MP, Chen X, Enyedi LB, Prakalapakorn SG, Materin MA, El-Dairi MA, Jaffe GJ, Freedman SF, Toth CA, Vajzovic L. Assessment of Macular Microvasculature in Healthy Eyes of Infants and Children Using OCT Angiography. Ophthalmology. 2019 Dec;126(12):1703-1711. doi: 10.1016/j.ophtha.2019.06.028. Epub 2019 Jul 15. PubMed 31548134 ↗
  • Chen X, Viehland C, Tran-Viet D, Prakalapakorn SG, Freedman SF, Izatt JA, Toth CA. Capturing Macular Vascular Development in an Infant With Retinopathy of Prematurity. JAMA Ophthalmol. 2019 Sep 1;137(9):1083-1086. doi: 10.1001/jamaophthalmol.2019.2165. No abstract available. PubMed 31246250 ↗
  • Wang KL, Chen X, Stinnett S, Tai V, Winter KP, Tran-Viet D, Toth CA. Understanding the variability of handheld spectral-domain optical coherence tomography measurements in supine infants. PLoS One. 2019 Dec 11;14(12):e0225960. doi: 10.1371/journal.pone.0225960. eCollection 2019. PubMed 31825990 ↗
  • Mangalesh S, Tran-Viet D, Pizoli C, Tai V, El-Dairi MA, Chen X, Viehland C, Edwards L, Finkle J, Freedman SF, Toth CA. Subclinical Retinal versus Brain Findings in Infants with Hypoxic Ischemic Encephalopathy. Graefes Arch Clin Exp Ophthalmol. 2020 Sep;258(9):2039-2049. doi: 10.1007/s00417-020-04738-0. Epub 2020 May 29. PubMed 32472201 ↗
  • Seely KR, Wang KL, Tai V, Prakalapakorn SG, Chiu SJ, Viehland C, Grace S, Izatt JA, Freedman SF, Toth CA. Auto-Processed Retinal Vessel Shadow View Images From Bedside Optical Coherence Tomography to Evaluate Plus Disease in Retinopathy of Prematurity. Transl Vis Sci Technol. 2020 Aug 7;9(9):16. doi: 10.1167/tvst.9.9.16. eCollection 2020 Aug. PubMed 32879772 ↗
  • Chen X, Imperio R, Seely KR, Viehland C, Izatt JA, Prakalapakorn SG, Freedman SF, Toth CA. Slow progressive perifoveal vascular formation in an infant with aggressive posterior retinopathy of prematurity. J AAPOS. 2020 Oct;24(5):323-326. doi: 10.1016/j.jaapos.2020.07.007. Epub 2020 Oct 9. PubMed 33045380 ↗
  • O'Sullivan ML, Ying GS, Mangalesh S, Tai V, Divecha HR, Winter KP, Toth CA, Chen X; BabySTEPS Group. Foveal Differentiation and Inner Retinal Displacement Are Arrested in Extremely Premature Infants. Invest Ophthalmol Vis Sci. 2021 Feb 1;62(2):25. doi: 10.1167/iovs.62.2.25. PubMed 33599735 ↗
  • Chen X, Tai V, McGeehan B, Ying GS, Viehland C, Imperio R, Winter KP, Raynor W, Tran-Viet D, Mangalesh S, Maguire MG, Toth CA; BabySTEPS Group. Repeatability and Reproducibility of Axial and Lateral Measurements on Handheld Optical Coherence Tomography Systems Compared with Tabletop System. Transl Vis Sci Technol. 2020 Oct 21;9(11):25. doi: 10.1167/tvst.9.11.25. eCollection 2020 Oct. PubMed 33150050 ↗
  • Shen LL, Mangalesh S, McGeehan B, Tai V, Sarin N, El-Dairi MA, Freedman SF, Maguire MG, Toth CA; BabySTEPS Group. Birth Weight Is a Significant Predictor of Retinal Nerve Fiber Layer Thickness at 36 Weeks Postmenstrual Age in Preterm Infants. Am J Ophthalmol. 2021 Feb;222:41-53. doi: 10.1016/j.ajo.2020.08.043. Epub 2020 Sep 4. PubMed 32891695 ↗
  • Mangalesh S, Wong BM, Chen X, Tran-Viet D, Stinnett SS, Sarin N, Winter KP, Vajzovic L, Freedman SF, Toth CA. Morphological characteristics of early- versus late-onset macular edema in preterm infants. J AAPOS. 2020 Oct;24(5):303-306. doi: 10.1016/j.jaapos.2020.06.006. Epub 2020 Sep 15. PubMed 32942022 ↗
  • Mangalesh S, McGeehan B, Tai V, Chen X, Tran-Viet D, Vajzovic L, Viehland C, Izatt JA, Cotten CM, Freedman SF, Maguire MG, Toth CA; Study of Eye Imaging in Preterm Infants Group. Macular OCT Characteristics at 36 Weeks' Postmenstrual Age in Infants Examined for Retinopathy of Prematurity. Ophthalmol Retina. 2021 Jun;5(6):580-592. doi: 10.1016/j.oret.2020.09.004. Epub 2020 Sep 11. PubMed 32927150 ↗
  • Mangalesh S, Sarin N, McGeehan B, Prakalapakorn SG, Tran-Viet D, Cotten CM, Freedman SF, Maguire MG, Toth CA; BabySTEPS Group. Preterm Infant Stress During Handheld Optical Coherence Tomography vs Binocular Indirect Ophthalmoscopy Examination for Retinopathy of Prematurity. JAMA Ophthalmol. 2021 May 1;139(5):567-574. doi: 10.1001/jamaophthalmol.2021.0377. PubMed 33792625 ↗
  • Campbell JP, Kalpathy-Cramer J, Erdogmus D, Tian P, Kedarisetti D, Moleta C, Reynolds JD, Hutcheson K, Shapiro MJ, Repka MX, Ferrone P, Drenser K, Horowitz J, Sonmez K, Swan R, Ostmo S, Jonas KE, Chan RV, Chiang MF; Imaging and Informatics in Retinopathy of Prematurity Research Consortium. Plus Disease in Retinopathy of Prematurity: A Continuous Spectrum of Vascular Abnormality as a Basis of Diagnostic Variability. Ophthalmology. 2016 Nov;123(11):2338-2344. doi: 10.1016/j.ophtha.2016.07.026. Epub 2016 Aug 31. PubMed 27591053 ↗
  • Maldonado RS, Toth CA. Optical coherence tomography in retinopathy of prematurity: looking beyond the vessels. Clin Perinatol. 2013 Jun;40(2):271-96. doi: 10.1016/j.clp.2013.02.007. PubMed 23719310 ↗
  • Zepeda EM, Shariff A, Gillette TB, Grant L, Ding L, Tarczy-Hornoch K, Cabrera MT. Vitreous Bands Identified by Handheld Spectral-Domain Optical Coherence Tomography Among Premature Infants. JAMA Ophthalmol. 2018 Jul 1;136(7):753-758. doi: 10.1001/jamaophthalmol.2018.1509. PubMed 29799932 ↗

Individual participant data

Plan to share: Yes — The Retinal Microanatomy in ROP Study (BabySTEPS2) data cannot be analyzed for publication until they are released by the study Principal Investigator upon final review and approval by the Data Safety and Monitoring Committee. BabySTEPS2 data will be made available as follows: A summary, de-identified data set available upon request through direct inquiries to the Study PI or Coordinating Center a year after publication. By the end of the funding period, de-identified SAS data sets and form images corresponding to all data collection forms, as well as key derived variables, will be put on file with a data repository. Researchers may request limited access data sets. The raw and analyzed imaging datasets will be made available after the completion of the Retinal Microanatomy in ROP Study. Approved recipients will need to enter into a data sharing agreement. Costs for compilation and access to the datasets will be the responsibility of the recipients.

Time frame: Data will be made available after the completion of the Retinal Microanatomy in ROP (BabySTEPS2) Study

Access criteria: Data requests must be submitted to the PI or the Coordinating Center. Approved recipients will need to enter into a data sharing agreement. Costs for compilation and access to the datasets will be the responsibility of the recipients.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2021 (actual). Primary completion is estimated for Mar 2027, 67 months after the start.

Of 28 non-industry interventional studies with no phase under Retinopathy of Prematurity, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's planned 67 months is above that.

Counting every sponsor, half of 30 studies reached it within 14 months; a quarter within 11 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2021
First posted
Aug 6, 2021
StartActual
Aug 16, 2021
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04995341
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Aug 6, 2021
Start date
Aug 16, 2021
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
May 22, 2026

Study contacts

Cynthia A Toth, MD
Contact
cynthia.toth@duke.edu
919-684-5631
Michelle N McCall, MCAPM, BA
Contact
michelle.mccall@duke.edu
919-684-0544
Cynthia A Toth, MD
principal investigator · Duke University Eye Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion